| ［1］ Chao MP, Majeti R， Weissman IL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer, 2012,12(1): 58-67. ［2］ Sick E, Jeanne A, Schneider C, et al. CD47 update: a multifaceted actor in the tumor microenvironment of potential therapeutic interest. Br J Pharmacol, 2012,167(7):1415-1430. ［3］ Chao MP, Jaiswal S, WeissmanTsukamoto R, et al. Calreticulin is the dominant prophagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med, 2010,2(63)：63ra94. ［4］ Jaiswal S, Chao MP, Majeti R, et al. Macrophages as mediators of tumor immunosurveillance. Trends Immunol, 2010,31(6):212-219. ［5］ Chao MP, Weissman IL, Majeti R. The CD47SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol, 2012,24(2):225-232. ［6］ Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell, 2009,138(2):286-299. ［7］ Sagawa M, Shimizu T, Fukushima N, et al. A new disulfidelinked dimer of a singlechain antibody fragment against human CD47 induces apoptosis in lymphoid malignant cells via the hypoxia inducible factor1α pathway. Cancer Sci, 2011,102(6):1208-1215. ［8］ Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res, 2010,71(4):1374-1384. ［9］ Chao MP, Alizadeh AA, Tang C, et al. AntiCD47 antibody synergizes with rituximab to promote phagocytosis and eradicate nonHodgkin lymphoma. Cell, 2010,142(5):699-713. ［10］ Chao MP, Tang C, Pachynski RK, et al. Extranodal dissemination of nonHodgkin lymphoma requires CD47 and is inhibited by antiCD47 antibody therapy. Blood, 2011,118(18):4890-4901. ［11］ Kim D, Wang J, Willingham SB, et al. AntiCD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia, 2012,26(12):2538-2545. ［12］ Edris B, Weiskopf K, Weissman IL, et al. Flipping the script on macrophages in leiomyosarcoma. Oncoimmunology, 2012,1(7):1202-1204. ［13］ Edris B, Weiskopf K, Volkmer AK, et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA, 2012,109(17):6656-6661. ［14］ Sick E, Boukhari A, Deramaudt T, et al. Activation of CD47 receptors causes proliferation of human astrocytoma but not normal astrocytes via an aktdependent pathway. Glia, 2011,59(2):308-319. ［15］ Zhao XW, van Beek EM, Schornagel K, et al. CD47signal regulatory protein α (SIRPα) interactions form a barrier for antibodymediated tumor cell destruction. Proc Natl Acad Sci USA, 2011,108(45):18342-18347. ［16］ Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47signal regulatory protein alpha (SIRPα) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA, 2012,109(17):6662-6667. ［17］ Hongrapipat J, Kopeckova P, Liu J, et al. Combination chemotherapy and photodynamic therapy with Fab′fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol Pharm, 2008,5(5):696-709. ［18］ Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumorinitiating cells. Proc Natl Acad Sci USA, 2009,106(33):14016-14021. ［19］ Kim MJ, Lee JC, Lee JJ, et al. Association of CD47 with natural killer cellmediated cytotoxicity of headandneck squamous cell carcinoma lines. Tumour Biol, 2008,29(1):28-34. |
